Promoter activity of Merkel cell Polyomavirus variants in human dermal fibroblasts and a Merkel cell carcinoma cell line.
Large T-antigen
Luciferase assay
MCC13 cells
MCPyV
Mutations
Non-coding control region
Journal
Virology journal
ISSN: 1743-422X
Titre abrégé: Virol J
Pays: England
ID NLM: 101231645
Informations de publication
Date de publication:
19 04 2020
19 04 2020
Historique:
received:
19
12
2019
accepted:
10
03
2020
entrez:
21
4
2020
pubmed:
21
4
2020
medline:
10
2
2021
Statut:
epublish
Résumé
Merkel cell polyomavirus (MCPyV) is a human polyomavirus that establishes a life-long harmless infection in most individuals, with dermal fibroblasts believed to be the natural host cell. However, this virus is the major cause of Merkel cell carcinoma (MCC), an aggressive skin cancer. Several MCPyV variants with polymorphism in their promoter region have been isolated, but it is not known whether these differences affect the biological properties of the virus. Using transient transfection studies in human dermal fibroblasts and the MCC cell line MCC13, we compared the transcription activity of the early and late promoters of the most commonly described non-coding control region MCPyV variant and six other isolates containing specific mutation patterns. Both the early and late promoters were significantly stronger in human dermal fibroblasts compared with MCC13 cells, and a different promoter strength between the MCPyV variants was observed. The expression of full-length large T-antigen, a viral protein that regulates early and late promoter activity, inhibited early and late promoter activities in both cell lines. Nonetheless, a truncated large T-antigen, which is expressed in virus-positive MCCs, stimulated the activity of its cognate promoter. The promoter activities of all MCPyV variants tested was stronger in human dermal fibroblasts, a cell line that supports viral replication, than in MCC13 cells, which are not permissive for MCPyV. Truncated large T-antigen, but not full-length large T-antigen stimulated viral promoter activity. Whether, the difference in promoter strength and regulation by large T-antigen may affect the replication and tumorigenic properties of the virus remains to be determined.
Sections du résumé
BACKGROUND
Merkel cell polyomavirus (MCPyV) is a human polyomavirus that establishes a life-long harmless infection in most individuals, with dermal fibroblasts believed to be the natural host cell. However, this virus is the major cause of Merkel cell carcinoma (MCC), an aggressive skin cancer. Several MCPyV variants with polymorphism in their promoter region have been isolated, but it is not known whether these differences affect the biological properties of the virus.
METHODS
Using transient transfection studies in human dermal fibroblasts and the MCC cell line MCC13, we compared the transcription activity of the early and late promoters of the most commonly described non-coding control region MCPyV variant and six other isolates containing specific mutation patterns.
RESULTS
Both the early and late promoters were significantly stronger in human dermal fibroblasts compared with MCC13 cells, and a different promoter strength between the MCPyV variants was observed. The expression of full-length large T-antigen, a viral protein that regulates early and late promoter activity, inhibited early and late promoter activities in both cell lines. Nonetheless, a truncated large T-antigen, which is expressed in virus-positive MCCs, stimulated the activity of its cognate promoter.
CONCLUSION
The promoter activities of all MCPyV variants tested was stronger in human dermal fibroblasts, a cell line that supports viral replication, than in MCC13 cells, which are not permissive for MCPyV. Truncated large T-antigen, but not full-length large T-antigen stimulated viral promoter activity. Whether, the difference in promoter strength and regulation by large T-antigen may affect the replication and tumorigenic properties of the virus remains to be determined.
Identifiants
pubmed: 32306957
doi: 10.1186/s12985-020-01317-x
pii: 10.1186/s12985-020-01317-x
pmc: PMC7168875
doi:
Substances chimiques
Antigens, Viral, Tumor
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
54Références
Oncotarget. 2018 Jul 31;9(59):31432-31447
pubmed: 30140381
PLoS One. 2018 Oct 23;13(10):e0206273
pubmed: 30352098
Proc Natl Acad Sci U S A. 2008 Oct 21;105(42):16272-7
pubmed: 18812503
J Gen Virol. 2015 Aug;96(8):2293-2303
pubmed: 25968129
Cell Host Microbe. 2016 Jun 8;19(6):775-87
pubmed: 27212661
Clin Vaccine Immunol. 2013 Mar;20(3):363-8
pubmed: 23302741
J Virol Methods. 2013 Jan;187(1):6-14
pubmed: 23085629
J Virol. 2013 Dec;87(24):13751-9
pubmed: 24109229
PLoS One. 2014 Sep 03;9(9):e106430
pubmed: 25184447
Front Microbiol. 2018 Apr 11;9:713
pubmed: 29696010
Clin Vaccine Immunol. 2011 Oct;18(10):1737-43
pubmed: 21880855
Orv Hetil. 2013 Jan 20;154(3):102-12
pubmed: 23315225
J Virol. 2010 Oct;84(20):10448-56
pubmed: 20686041
Emerg Infect Dis. 2008 Sep;14(9):1491-3
pubmed: 18760031
Br J Cancer. 2013 Feb 19;108(3):629-37
pubmed: 23322199
PLoS Pathog. 2009 Mar;5(3):e1000363
pubmed: 19325891
Cancers (Basel). 2014 Jun 27;6(3):1267-97
pubmed: 24978434
APMIS. 2020 Jan 28;:
pubmed: 31990105
Blood. 2010 Dec 9;116(24):5280-4
pubmed: 20817850
J Virol. 1987 Apr;61(4):1296-9
pubmed: 3029428
PLoS One. 2012;7(6):e38499
pubmed: 22723863
J Gen Virol. 2012 Aug;93(Pt 8):1780-1794
pubmed: 22552944
Curr Opin Virol. 2015 Apr;11:38-43
pubmed: 25681708
J Clin Virol. 2013 Sep;58(1):288-91
pubmed: 23829968
Science. 2008 Feb 22;319(5866):1096-100
pubmed: 18202256
Lancet Oncol. 2012 Apr;13(4):339-40
pubmed: 22577663
Infect Genet Evol. 2017 Oct;54:18-38
pubmed: 28634106
Int J Mol Sci. 2017 Nov 14;18(11):
pubmed: 29135936
J Infect Dis. 2018 Apr 23;217(10):1601-1611
pubmed: 29409030
J Invest Dermatol. 2009 Jan;129(1):248-50
pubmed: 18633441
J Invest Dermatol. 2015 May;135(5):1415-1424
pubmed: 25313532
J Infect Dis. 2016 Jun 1;213(11):1708-16
pubmed: 26908721
J Virol. 2016 Dec 16;91(1):
pubmed: 27795410
J Virol. 2014 Mar;88(6):3144-60
pubmed: 24371076
Cell Host Microbe. 2010 Jun 25;7(6):509-15
pubmed: 20542254
J Virol. 2018 Mar 14;92(7):
pubmed: 29343574
Lab Invest. 1987 Mar;56(3):302-12
pubmed: 3546933
PLoS One. 2018 Jun 26;13(6):e0199171
pubmed: 29944671
J Gen Virol. 2016 Jul;97(7):1647-1657
pubmed: 27031170
Cancer Res. 2008 Jul 1;68(13):5009-13
pubmed: 18593898
J Virol. 2015 Jan 15;89(2):1340-7
pubmed: 25392214
Cancer Res. 2015 Mar 15;75(6):1068-79
pubmed: 25596282
PLoS One. 2015 Nov 06;10(11):e0142329
pubmed: 26544690
Proc Natl Acad Sci U S A. 2017 May 16;114(20):E4040-E4047
pubmed: 28461484
J Exp Med. 2008 Apr 14;205(4):841-52
pubmed: 18347101